A study published in Frontiers in Oncology showed that consecutive hypoalbuminemia is a robust outcome predictor in patients with diffuse large B-cell lymphoma (DLBCL).
To conduct this study, researchers retrospectively analyzed 574 patients with de novo DLBCL who were all allocated into either a a training cohort (n=78) or a validation cohort (n=296). They used Kaplan-Meier and Cox proportional hazard regression modelling to assess overall survival (OS) and progression-free survival (PFS).
According to the results, 58.6% of patients had low serum albumin at diagnosis, of which 80 presented with consecutive hypoalbuminemia at the end of treatment. The researchers noted that patients with consecutive hypoalbuminemia showed inferior OS and PFS (P=0.010 and P=0.079, respectively). They observed similar survival differences in the independent validation cohort (P=0.006 and P=0.030, respectively). Furthermore, multivariable analysis showed that consecutive hypoalbuminemia was an independent prognostic factor of OS (relative risk [RR], 2.249; 95% confidence interval [CI], 1.441-3.509; P<0.001) and PFS (RR, 2.001; 95% CI, 1.443-2.773; P<0.001).
“Consecutive hypoalbuminemia is a simple and effective adverse prognostic factor in patients with DLBCL, which reminds us to pay more attention to patients with low serum albumin at end of treatment during follow-up,” the researchers concluded.